Published in Mol Cancer Ther on January 01, 2008
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell (2012) 2.08
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat (2009) 1.34
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget (2011) 1.27
Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell (2015) 1.20
Advances in understanding the leukaemia microenvironment. Br J Haematol (2014) 1.19
The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer (2012) 1.18
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica (2010) 1.14
Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ (2014) 1.10
The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol (2013) 1.09
The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol (2011) 1.08
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia (2010) 1.07
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia (2011) 1.06
Chronic myeloid leukemia stem cell biology. Curr Hematol Malig Rep (2012) 1.05
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mol Cancer (2014) 1.01
A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica (2015) 0.99
Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res (2013) 0.98
MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol (2013) 0.95
Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis (2013) 0.95
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget (2015) 0.91
Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin Cancer Biol (2008) 0.90
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget (2014) 0.89
Development of an effective therapy for chronic myelogenous leukemia. Cancer J (2011) 0.87
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood (2012) 0.86
Why doesn't imatinib cure chronic myeloid leukemia? Oncologist (2010) 0.80
In vivo fluorescence imaging reveals the promotion of mammary tumorigenesis by mesenchymal stromal cells. PLoS One (2013) 0.79
Cancer associated fibroblasts in hematological malignancies. Oncotarget (2015) 0.79
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature (2016) 0.78
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol (2010) 0.78
Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica (2011) 0.78
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget (2016) 0.76
Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. Leukemia (2016) 0.76
Myeloid malignancies and the microenvironment. Blood (2016) 0.75
Nanomechanical measurement of adhesion and migration of leukemia cells with phorbol 12-myristate 13-acetate treatment. Int J Nanomedicine (2016) 0.75
Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes. Oncotarget (2016) 0.75
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators Inflamm (2015) 0.75
Integration of hypoxic HIF-α signaling in blood cancers. Oncogene (2017) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One (2009) 3.89
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood (2007) 3.29
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer (2007) 3.10
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol (2009) 3.07
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol (2007) 2.92
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood (2007) 2.91
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol (2009) 2.78
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells (2009) 2.68
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst (2008) 2.64
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2008) 2.54
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol (2013) 2.42
Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med (2007) 2.38
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res (2005) 2.37
Decay-accelerating factor modulates induction of T cell immunity. J Exp Med (2005) 2.34
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther (2008) 2.31
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol (2014) 2.26
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
Discontinuation of imatinib therapy after achieving a molecular response. Blood (2004) 2.23
Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol (2006) 2.22
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma (2007) 2.21
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood (2005) 2.21
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res (2009) 2.19